List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/42368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Intraoperative Microlesion Effect Positively Correlates With the Short-Term Clinical Effect of Deep Brain Stimulation in Parkinson's Disease. Neuromodulation, 2023, 26, 459-465.	0.8	9
2	Serendipitous Stimulation of Nucleus Basalis of Meynert—The Effect of Unintentional, Long-Term High-Frequency Stimulation on Cognition in Parkinson's Disease. Journal of Clinical Medicine, 2022, 11, 337.	2.4	1
3	Self-Reported Visual Complaints in People with Parkinson's Disease: A Systematic Review. Journal of Parkinson's Disease, 2022, 12, 785-806.	2.8	8
4	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. Movement Disorders, 2022, 37, 713-723.	3.9	27
5	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. Progress in Brain Research, 2022, 269, 345-371.	1.4	8
6	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. Aging Brain, 2022, 2, 100039.	1.3	15
7	Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications― Parkinsonism and Related Disorders, 2022, 97, 99-100.	2.2	3
8	Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 2275.	2.4	8
9	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. Movement Disorders, 2021, 36, 642-650.	3.9	41
10	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism and Related Disorders, 2021, 83, 79-85.	2.2	39
11	Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data. Scientific Reports, 2021, 11, 11751.	3.3	17
12	Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies. Parkinsonism and Related Disorders, 2021, 89, 38-40.	2.2	1
13	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinson's disease: A Prospective Analysis of the Thai Apomorphine Registry. Parkinsonism and Related Disorders, 2021, 91, 146-151.	2.2	6
14	Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait. Parkinsonism and Related Disorders, 2021, 91, 96-101.	2.2	9
15	Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants. Npj Parkinson's Disease, 2021, 7, 113.	5.3	6
16	Postural and gait symptoms in de novo Parkinson's disease patients correlate with cholinergic white matter pathology. Parkinsonism and Related Disorders, 2021, 93, 43-49.	2.2	6
17	Effectiveness of ReSET; a strategic executive treatment for executive dysfunctioning in patients with Parkinson's disease. Neuropsychological Rehabilitation, 2020, 30, 67-84.	1.6	11
18	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 437-450.	6.4	54

#	Article	IF	CITATIONS
19	Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing. Journal of Parkinson's Disease, 2020, 10, 1675-1693.	2.8	12
20	Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. Journal of Parkinson's Disease, 2020, 10, 935-944.	2.8	8
21	Multicenter Validation of Metabolic Abnormalities Related to <scp>PSP</scp> According to the <scp>MDSâ€PSP</scp> Criteria. Movement Disorders, 2020, 35, 2009-2018.	3.9	18
22	Long-Term Patient-Reported Outcome of Radiofrequency Thalamotomy for Tremor. Stereotactic and Functional Neurosurgery, 2020, 98, 187-192.	1.5	8
23	Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology. BMC Neurology, 2020, 20, 245.	1.8	17
24	Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy. Journal of Clinical Medicine, 2020, 9, 1855.	2.4	10
25	A <scp>Large cale</scp> Full <scp><i>GBA1</i></scp> Gene Screening in Parkinson's Disease in the Netherlands. Movement Disorders, 2020, 35, 1667-1674.	3.9	41
26	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	2.8	7
27	Introduction: The Gut-Brain Axis in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, S279-S279.	2.8	2
28	Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation—A Prospective Noninferiority Study. Neuromodulation, 2019, 22, 472-477.	0.8	18
29	rTMS treatment of visual hallucinations using a connectivity-based targeting method - A case study. Brain Stimulation, 2019, 12, 1622-1624.	1.6	6
30	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. New England Journal of Medicine, 2019, 380, 315-324.	27.0	225
31	Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism and Related Disorders, 2019, 64, 40-49.	2.2	91
32	[¹⁸ F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. Movement Disorders, 2019, 34, 924-926.	3.9	20
33	Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Parkinson's disease dementia. Parkinsonism and Related Disorders, 2018, 52, 102-106.	2.2	11
34	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. Clinical Neuropharmacology, 2018, 41, 14-19.	0.7	11
35	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's Disease, 2018, 8, 71-84.	2.8	12
36	Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature. Neuromodulation, 2018, 21, 527-531.	0.8	2

#	Article	IF	CITATIONS
37	Deep Brain Stimulation for Essential Tremor: A Comparison of Targets. World Neurosurgery, 2018, 110, e580-e584.	1.3	38
38	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 749-759.	10.2	203
39	Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases. Contact Dermatitis, 2018, 79, 316-318.	1.4	13
40	Successful treatment of intractable visual hallucinations with 5-HT2Aantagonist ketanserin. BMJ Case Reports, 2018, 2018, bcr-2018-224340.	0.5	4
41	Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 283-289.	6.3	21
42	Objective Versus Subjective Measures of Executive Functions: Predictors of Participation and Quality of Life in Parkinson Disease?. Archives of Physical Medicine and Rehabilitation, 2017, 98, 2181-2187.	0.9	20
43	Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle. Movement Disorders, 2017, 32, 1253-1254.	3.9	73
44	A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. Journal of Parkinson's Disease, 2017, 7, 749-754.	2.8	39
45	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism and Related Disorders, 2017, 45, 33-38.	2.2	34
46	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Movement Disorders, 2017, 32, 1482-1486.	3.9	67
47	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands. Environment International, 2017, 107, 100-110.	10.0	121
48	The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa–carbidopa intestinal gel. Journal of Multidisciplinary Healthcare, 2017, Volume 10, 13-27.	2.7	17
49	Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism and Related Disorders, 2016, 33, S2-S8.	2.2	19
50	The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. Parkinsonism and Related Disorders, 2016, 33, S22-S27.	2.2	9
51	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S49-S55.	2.2	31
52	How Many Patients would Benefit from Steering Technology for Deep Brain Stimulation?. Brain Stimulation, 2016, 9, 144-145.	1.6	10
53	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism and Related Disorders, 2016, 27, 35-40.	2.2	40
54	Mental slowness in patients with Parkinson's disease: Associations with cognitive functions?. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 844-852.	1.3	26

#	Article	IF	CITATIONS
55	Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 90-95.	2.2	36
56	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. Parkinsonism and Related Disorders, 2016, 22, e27-e28.	2.2	0
57	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 23, 17-22.	2.2	63
58	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. Parkinsonism and Related Disorders, 2016, 22, e87-e88.	2.2	0
59	Diepe hersenstimulatie bij de ziekte van Parkinson. , 2016, , 77-83.		0
60	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. BMC Neurology, 2015, 15, 236.	1.8	14
61	Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 89-103.	0.7	48
62	Improved Gait Performance in a Patient With Hereditary Spastic Paraplegia After a Continuous Intrathecal Baclofen Test Infusion and Subsequent Pump Implantation: A Case Report. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1166-1169.	0.9	23
63	Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study. Journal of Psychosomatic Research, 2015, 79, 190-194.	2.6	46
64	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 635-639.	2.2	20
65	Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review. Brain Stimulation, 2015, 8, 983-985.	1.6	0
66	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. Parkinsonism and Related Disorders, 2015, 21, 1023-1030.	2.2	126
67	Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson's disease. International Archives of Occupational and Environmental Health, 2015, 88, 227-234.	2.3	12
68	Lateral and Medial Ventral Occipitotemporal Regions Interact During the Recognition of Images Revealed from Noise. Frontiers in Human Neuroscience, 2015, 9, 678.	2.0	5
69	Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands. Occupational and Environmental Medicine, 2014, 71, 757-764.	2.8	29
70	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology, 2014, 37, 9-16.	0.7	62
71	Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2199-2206.	0.9	34
72	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking. PLoS ONE, 2014, 9, e95297.	2.5	52

#	Article	IF	CITATIONS
73	Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurology, The, 2013, 12, 37-44.	10.2	607
74	Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism and Related Disorders, 2013, 19, 501-507.	2.2	99
75	The added value of semimicroelectrode recording in deep brain stimulation of the subthalamic nucleus for Parkinson disease. Neurosurgical Focus, 2013, 35, E3.	2.3	6
76	The treatment of early Parkinson's disease: levodopa rehabilitated. Practical Neurology, 2011, 11, 145-152.	1.1	19
77	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. CNS Neuroscience and Therapeutics, 2011, 17, 428-441.	3.9	61
78	Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. Movement Disorders, 2011, 26, 142-147.	3.9	48
79	Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Movement Disorders, 2011, 26, 331-334.	3.9	27
80	SCOPAâ€cognition cutoff value for detection of Parkinson's disease dementia. Movement Disorders, 2011, 26, 1881-1886.	3.9	30
81	Lasting visual hallucinations in visual deprivation; fMRI correlates and the influence of rTMS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1295-1296.	1.9	16
82	Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism and Related Disorders, 2010, 16, 71-72.	2.2	42
83	Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism and Related Disorders, 2010, 16, 270-274.	2.2	48
84	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
85	Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain, 2009, 132, 2980-2993.	7.6	163
86	Characteristics of dystonia in the 18p deletion syndrome, including a new case. Clinical Neurology and Neurosurgery, 2009, 111, 880-882.	1.4	22
87	The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations. Clinical Neuropharmacology, 2009, 32, 266-268.	0.7	19
88	Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. Movement Disorders, 2008, 23, 2404-2406.	3.9	87
89	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement Disorders, 2008, 23, 1532-1540.	3.9	33
90	Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Movement Disorders, 2008, 23, 1906-1912.	3.9	66

#	Article	IF	CITATIONS
91	Continuous Drug Delivery with Levodopa/Carbidopa Infusion: <i>Review and First Data of a Dutch Cohort</i> . CNS Spectrums, 2008, 13, 11-14.	1.2	0

1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

93	Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Movement Disorders, 2007, 22, 2430-2435.	3.9	50
94	Fallacious falls. Journal of Neurology, 2005, 252, 1271-1273.	3.6	8
95	Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2509-2518.	27.0	1,111
96	Levodopa-Induced Response Fluctuations in Patients with Parkinson???s Disease. CNS Drugs, 2003, 17, 475-489.	5.9	36
97	Quick Titration of Pergolide in Cotreatment with Domperidone Is Safe and Effective. Clinical Neuropharmacology, 2001, 24, 177-180.	0.7	15
98	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders, 2001, 16, 197-201.	3.9	111
99	Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson??s Disease. Clinical Pharmacokinetics, 1999, 37, 257-271.	3.5	66
100	The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study. Movement Disorders, 1998, 13, 52-55.	3.9	19
101	Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. Movement Disorders, 1998, 13, 176-178.	3.9	20
102	Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharmaceutical Research, 1997, 14, 1804-1810.	3.5	52
103	Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. International Journal of Bio-medical Computing, 1994, 36, 143-150.	0.5	3
104	Population Pharmacokinetics of Apomorphine in Patients with Parkinson's Disease. Drug Investigation, 1994, 7, 183-190.	0.6	8